Skip to main content
Log in

Safety, Efficacy and Pharmacokinetics of Ritonavir 400mg/Saquinavir 400mg Twice Daily plus Rifampicin Combined Therapy in HIV Patients with Tuberculosis

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: To assess the drug concentrations, efficacy and safety of concomitant use of rifampicin and regimens containing ritonavir/saquinavir (400mg/400mg twice daily) in tuberculosis-HIV treatment-naive patients.

Design and methods: This was an open-label, non-randomised, multiple-dose study. On study day (D)1, tuberculosis treatment (rifampicin 600mg/isoniazid 400mg per day fasting plus pyrazinamide 2 g/day) was introduced in 30 patients. On D31, highly active antiretroviral therapy (HAART) consisting of two nucleoside analogues plus ritonavir/saquinavir 400mg/400mg twice daily was initiated (n = 20).

The pharmacokinetics were assayed with a validated reversed-phase HPLC method before the introduction of HAART on D30 (for rifampicin), after 30 days of HAART at D60 (for rifampicin plus ritonavir/saquinavir), and at the end of the study (without rifampicin) on D210 (for ritonavir/saquinavir). Clinical evaluations were performed on a monthly basis. CD4 counts and viral load were collected on D30, D60 and D180. Genotyping test for HIV was collected at baseline and at D180. Primary endpoints were drug concentration and viral load at D180 (<80 copies/mL). Secondary endpoints were presence of grade 3 and serious adverse events, clinical improvement, CD4 count and genotypic resistance to ritonavir/saquinavir.

Results: Ten patients dropped out of the study during tuberculosis therapy alone. Mean (± SD) baseline CD4 count (on D30) was 151.89 (± 146.77) cells/mm3 and viral load was 5.34 (± 0.4) log. During the antiretroviral therapy, 15 patients dropped out, 14 because of adverse events. One patient (of five) presented a viral load of <80 copies/mL at D180. All but one patient increased CD4 counts from baseline. No genotypic resistance was detected. Clinical improvement was evident in all five patients who tolerated the therapy. Serum concentrations of ritonavir/saquinavir and rifampicin remained within the therapeutic range.

Conclusions: Therapeutic concentrations of the studied drugs and reduction of viral load were achieved; adverse events are the main limitation of use of a ritonavir/saquinavir regimen in treatment-naive patients, but its clinical benefits were evident.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II

Similar content being viewed by others

References

  1. Pan American Health Organization. Health situation in the Americas: basic indicators 2004 [online]. Available from URL: http://www.paho.org/english/dd/aids/bi-brochure2004 [Accessed 2006 Feb 16]

  2. Gadelha A, Accácio N, Costa RLB, et al. Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. Rev Inst Med Trop São Paulo 2002; 44(4): 179–86

    Article  PubMed  Google Scholar 

  3. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367–73

    Article  PubMed  CAS  Google Scholar 

  4. Strayhorn VA, Baciewich AM, Self TH. Update on rifampin drug interaction, III. Arch Intern Med 1997; 157: 2453–8

    Article  PubMed  CAS  Google Scholar 

  5. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug to drug interaction in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000; 30Suppl. 2: S123–9

    Article  PubMed  CAS  Google Scholar 

  6. Veldkamp AI, Hoetelmans RM, Beijnen JH, et al. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586

    Article  PubMed  CAS  Google Scholar 

  7. Ministério da Saude, Programa de DST/Aids. Brazil. Programa Nacional de Controle de Doenças Sexualmente Transmissíveis/Aids 2001 [online]. Available from URL: http://www.aids.gov.br [Accessed 2006 Jul 12]

  8. II Consenso Brasileiro de tuberculose: Diretrizes Brasileiras para tuberculose 2004: Jornal Brasileiro de Pneumologia 2004; 30 (S1)

  9. Grinsztejn B, Fandinho FCO, Veloso VG, et al. Mycobacteremia in patients with the acquired immunodeficiency syndrome. Arch Intern Med 1997; 157(20): 2359–63

    Article  PubMed  CAS  Google Scholar 

  10. The AIDS Clinical Trials Group (ACTG). Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institute of Health, August 1992 [online]. Available from URL: http://aactg.s-3.com. (R01–00100) [Accessed 2006 Jul 12]

  11. MMWR updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors, version 1.20.2004. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for using antiretroviral agents among HIV-infected adults and adolescents [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/00052295.htm [Accessed 2006 Jul 12]

  12. Ministerio da Saude, Programa da DST/Aids. 2000. Brasil. Programa Nacional de Controle de Doenças Sexualmente Transmissíveis/Aids Min. Saúde. 22/09/2000

  13. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach, 2003 [online]. Available from URL: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf [Accessed 2006 Jul 12]

  14. La Porte CJL, Colbers EPH, Berts r, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553–60

    Article  PubMed  Google Scholar 

  15. Burman WJ, Galiicano K, Peloquim C. Therapeutic implication of drug interaction in the treatment of HIV and tuberculosis. Clin Infect Dis 1999; 28: 419–29

    Article  PubMed  CAS  Google Scholar 

  16. Berning SE, Huitt GA, Iseman MD, et al. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327: 1817–8

    Article  PubMed  CAS  Google Scholar 

  17. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534–9

    PubMed  CAS  Google Scholar 

  18. Lea AP, Faulds D. Ritonavir. Drugs 1996; 52(4): 541–6

    Article  PubMed  CAS  Google Scholar 

  19. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir or efavirenz. AIDS 2001; 15: 1679–86

    Article  PubMed  CAS  Google Scholar 

  20. Moreno S, Podzamczer D, Blásques R, et al. Treatment of tuberculosis in HIV infected patient: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampicin. AIDS 2001; 15(9): 1185–7

    Article  PubMed  CAS  Google Scholar 

  21. Ribera E, Azuaje C, Lopes RM, et al. Once daily regimen of saquinavir ritonavir didanosine and lamivudine in HIV infected patients with standard tuberculosis therapy. J Acquir Immune Defic Syndr 2005; 40(3): 317–23

    Article  PubMed  CAS  Google Scholar 

  22. Data on file F Hoffmann-la Roche Ltd. Preliminary report study bpl8180: effect of multiple dose rifampicin on the steady-state pharmacokinetics of saquinavir combined with low dose ritonavir and vice versa in healthy volunteers; 2005 Mar

  23. Witvrouw M, Pannecouque C, Desmyter J, et al. In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Res 2000; 46: 215–21

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the Brazilian Ministry of Health (DST/AIDS division), Abbott and Roche Pharmaceuticals, and the Ministry of Science and Technology (Pronex 98 and Millenio-Rede TB).

We thank Carla M. Vorsatz who kindly reviewed this paper and the day-clinical team for their special dedication: Liane Maria Braga da Silveira, Vania Braz Assanti, Luci Alves, Solange Alves da Cruz, Marcia Regina Lyra da Silva and Sonilde Mello Fasollo.

The authors have no potential conflicts of interest that are directly relevant to the contents of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Valeria Cavalcanti Rolla.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rolla, V.C., da Silva Vieira, M.A., Pinto, D.P. et al. Safety, Efficacy and Pharmacokinetics of Ritonavir 400mg/Saquinavir 400mg Twice Daily plus Rifampicin Combined Therapy in HIV Patients with Tuberculosis. Clin. Drug Investig. 26, 469–479 (2006). https://doi.org/10.2165/00044011-200626080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626080-00005

Keywords

Navigation